Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
XBIT
XBiotech Inc.
Core products are monoclonal antibody therapeutics derived from the True Human platform.
|
$78.05M |
$2.58
-2.83%
|
|
TVGN
Tevogen Bio Holdings Inc.
ExacTcell off-the-shelf T cell therapies and the TVGN 489 program position Tevogen as a cell therapy biotech focused on oncology and infectious disease.
|
$76.52M |
$0.37
-4.79%
|
|
IGMS
IGM Biosciences, Inc.
IGMS's engineered antibodies are monoclonal antibody therapeutics, a core product category.
|
$76.35M |
$1.27
|
|
EQ
Equillium, Inc.
Equillium's pipeline focuses on immunology/inflammatory diseases, aligning with Immunology Therapeutics.
|
$76.16M |
$1.20
-6.64%
|
|
KPTI
Karyopharm Therapeutics Inc.
Karyopharm's core business is oncology-focused biotechnology/pharmaceuticals, including the approved cancer therapy XPOVIO (selinexor) and an oncology pipeline.
|
$75.27M |
$8.69
+6.30%
|
|
VRCA
Verrica Pharmaceuticals Inc.
VP-315 is a peptide therapeutic for basal cell carcinoma, a clear major pipeline asset.
|
$75.05M |
$7.86
-2.00%
|
|
COEP
Coeptis Therapeutics, Inc.
GEAR Cell Therapy Platform is a core cell therapy biotech asset.
|
$75.00M |
$14.23
-3.20%
|
|
VANI
Vivani Medical, Inc.
Vivani's NanoPortal is a proprietary drug-implant platform enabling ultra long-acting, localized drug delivery.
|
$74.65M |
$1.30
+3.17%
|
|
MNOV
MediciNova, Inc.
MN-166 (ibudilast) and MN-001 (tipelukast) are oral small-molecule therapeutics in MediciNova's development pipeline.
|
$74.55M |
$1.52
+7.39%
|
|
CPIX
Cumberland Pharmaceuticals Inc.
Caldolor is a non-opioid IV analgesic, aligning CPIX with non-opioid pain management products.
|
$74.05M |
$4.81
-0.41%
|
|
ENTX
Entera Bio Ltd.
Entera Bio's N-Tab platform is a drug-delivery platform enabling oral administration of large-molecule peptides.
|
$73.06M |
$1.63
-6.32%
|
|
ALXO
ALX Oncology Holdings Inc.
ALX Oncology explicitly focuses on cancer therapies (immuno-oncology), placing it under Biotech - Oncology.
|
$72.29M |
$1.36
+9.68%
|
|
SRTS
Sensus Healthcare, Inc.
Sensus manufactures medical devices and biometric sensing technologies, including SRT therapy systems and related imaging components.
|
$72.17M |
$4.42
+0.68%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$72.13M |
$7.22
|
|
ADAG
Adagene Inc.
Core focus on monoclonal antibody therapeutics (ADG126 and related SAFEbody-based antibodies).
|
$72.08M |
$1.71
+3.64%
|
|
CRVO
CervoMed Inc.
Neflamapimod is an orally administered, small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$71.57M |
$7.77
-1.27%
|
|
IFRX
InflaRx N.V.
Vilobelimab is an anti-C5a monoclonal antibody, making InflaRx's core product line Monoclonal Antibody Therapeutics.
|
$70.46M |
$1.07
-1.38%
|
|
QDMI
QDM International Inc.
Health/medical insurance products are distributed via the company’s insurance brokerage activities.
|
$69.94M |
$41.43
|
|
ATYR
aTyr Pharma, Inc.
Efzofitimod is a biologic immunomodulator addressing inflammation in ILD, aligning with Immunology Therapeutics.
|
$69.84M |
$0.71
-1.67%
|
|
NNBR
NN, Inc.
Precision medical device components manufacturing, including implant-related parts (Medical Device Components).
|
$68.91M |
$1.35
+2.65%
|
|
TCRX
TScan Therapeutics, Inc.
Directly related to cell therapy products (TCR-T therapies) and platform-enabled manufacturing via ImmunoBank/T-Plex.
|
$68.67M |
$1.24
+4.66%
|
|
GOCO
GoHealth, Inc.
GoHealth's core offering is health insurance enrollment and management for Medicare plans.
|
$68.09M |
$2.35
-0.42%
|
|
IMUX
Immunic, Inc.
Immunic's lead programs are oral, small-molecule therapeutics (e.g., vidofludimus calcium and IMU-856).
|
$68.07M |
$0.69
+0.07%
|
|
CMPX
Compass Therapeutics, Inc.
Compass Therapeutics is an oncology-focused biotech developing cancer therapies, anchoring its business in oncology.
|
$67.55M |
$5.33
+3.19%
|
|
VATE
INNOVATE Corp.
MediBeacon and R2 Technologies manufacture medical devices/biometrics (skin therapy devices and transdermal kidney function monitoring).
|
$67.48M |
$5.02
-5.10%
|
|
SOTK
Sono-Tek Corporation
Medical device coatings are a key application (balloon catheters, stents), linking Sono-Tek to Medical Devices & Equipment.
|
$67.31M |
$4.32
+2.37%
|
|
PMVP
PMV Pharmaceuticals, Inc.
PMVP is a biotech company focused on oncology, developing rezatapopt to restore p53 function in TP53-mutant cancers, representing its core product category.
|
$66.77M |
$1.25
-0.40%
|
|
RFL
Rafael Holdings, Inc.
NPC1 rare-disease program (Trappsol Cyclo) places Rafael Holdings in the Biotech - Rare Diseases category.
|
$66.27M |
$1.27
+4.51%
|
|
MGX
Metagenomi, Inc. Common Stock
MGX's core platform is gene therapy/gene editing tools enabling therapeutic gene modification, including in vivo MGX-1.00 programs.
|
$65.31M |
$1.78
+2.30%
|
Showing page 27 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
